Advertisement
Mayo Clinic Proceedings Home

Thrombotic Thrombocytopenic Purpura: Successful Treatment Unlocks Etiologic Secrets*

      The cause of platelet agglutination in thrombotic thrombocytopenic purpura has been an enigma. Current evidence indicates that the interaction of platelets with a platelet-aggregating factor or unusually large multimers of factor VIII:von Willebrand factor, or both, may cause the abnormal platelet agglutination. Recent success in the treatment of thrombotic thrombocytopenic purpura with intravenous infusion of immunoglobulin suggests that the abnormal platelet agglutination in thrombotic thrombocytopenic purpura may reflect a deficiency of immunoglobulins that normally inhibit platelet-aggregating factors or large multimers of factor VIII:von Willebrand factor.
      In 1924, Moschcowitz initially described a fulminant febrile illness in a 16-year-old girl characterized by the diffuse deposition of hyaline thrombi in terminal arterioles.
      • Moschcowitz E
      Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.
      • Moschcowitz E
      An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease.
      In this original description of thrombotic thrombocytopenic purpura (TTP), Moschcowitz reported pallor, petechiae, fever, and slight paralysis. Laboratory studies revealed anemia and proteinuria. Nucleated erythrocytes were present in the peripheral blood smear; no schistocytes were described. No platelet count was obtained. At autopsy, hyaline thrombi were seen in “every section of heart muscle”; occasional thrombi were present in the spleen, liver, and kidneys. Moschcowitz stated, incorrectly, that the hyaline thrombi resulted from the agglutination of erythrocytes. He concluded that a toxin with pronounced hemolytic and agglutinating properties was the cause of the diffuse thrombotic process.
      TTP is a very rare disease. Petitt
      • Petitt RM
      Thrombotic thrombocytopenic purpura: a thirty year review.
      calculated an incidence of about one case per million population in Olmsted and Fillmore counties in his review of the Mayo Clinic experience for a 30-year period (1950 through 1979). The peak incidence is in the fourth decade of life, and 60% of cases occur in women.
      • Ridolfi RL
      • Bell WR
      Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature.

      MANIFESTATIONS

      The characteristic clinical pentad of TTP consists of thrombocytopenic purpura, microangio pathic hemolytic anemia, varying neurologic symptoms or signs, renal disease, and fever.
      • Ridolfi RL
      • Bell WR
      Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature.
      Clinically, the thrombocytopenia, which is attributable to diffuse platelet agglutination, may produce various bleeding complications such as petechiae, purpura, epistaxis, and cerebral and retinal hemorrhages. Neurologic manifestations include headache, confusion, aphasia, transient paresis, ataxia, sensory disturbances, and coma. Hematuria, proteinuria, and renal insufficiency (occasionally, acute renal failure) are the renal abnormalities. The cause of the moderate increases in body temperature is unknown. Anemia is frequently severe, the hemoglobin concentration being less than 5.5 g/dl in 30% of the patients.
      • Amorosi EL
      • Ultmann JE
      Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature.
      Consistent with this nonimmune intravascular hemolytic process, the peripheral blood smear demonstrates schistocytes without spherocytes. The indirect bilirubin, lactate dehydrogenase, reticulocyte count, and plasma hemoglobin values are increased, and hemosiderin is present in the urine. Additionally, haptoglobin is decreased or absent, and the direct Coombs test is negative. Thrombocytopenia is pronounced; platelet counts seldom exceed 20,000/mm3. Marrow megakaryocytes are normal or increased. Although fibrinogen may be consumed inadvertently during the process of diffuse platelet agglutination, mild disseminated intravascular coagulation is uncommon. Other clinical manifestations may include cardiac dysfunction, hepatosplenomegaly, and pancreatitis.

      DIAGNOSIS

      The diagnosis of TTP is suggested by the aforementioned clinical pentad; no specific diagnostic test exists. The presence of hyaline thrombi in biopsy specimens of skin, subcutaneous tissue, muscle, bone marrow, gingiva, or lymph nodes lends support to the diagnosis. These microvascular occlusions are evidence of the diffuse platelet agglutination that characterizes TTP. The differential diagnosis of TTP includes the hemolytic uremic syndrome, disseminated intravascular coagulation, autoimmune hemolytic anemia, immune thrombocytopenic purpura, Evans' syndrome, immune-mediated microangiopathy (such as systemic lupus erythematosus), subacute bacterial endocarditis, nonbacterial thrombotic endocarditis, meningococcemia, disseminated carcinomatosis, malignant hypertension, eclampsia, and the HELLP (hemolysis with elevated liver enzymes and low platelet count) preeclamptic syndrome.
      • Weinstein L
      Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension and pregnancy.
      The hemolytic-uremic syndrome may occur in adults; although similar to TTP clinically, the platelet agglutination is primarily limited to the kidney. The local absence of fibrinolytic activity in thrombosed vascular lesions distinguishes TTP from other disseminated intravascular coagulopathies.
      • Kwaan HC
      The role of fibrinolysis in thrombotic thrombocytopenic purpura.

      ETIOLOGY AND PATHOGENESIS

      The cause of TTP is unknown. Associations have been observed with pregnancy, toxins, drugs, and various immunologic disorders. Some investigators have suggested that any episode characterized by tissue necrosis (such as an injury, infection, or surgical procedure) may precipitate TTP.
      • Moake JL
      • Rudy CK
      • Troll JH
      • Weinstein MJ
      • Colannino NM
      • Azocar J
      • Seder RH
      • Hong SL
      • Deykin D
      Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.
      Specific etiologic considerations have included the following: nonspecific tissue factors,
      • Moake JL
      • Rudy CK
      • Troll JH
      • Weinstein MJ
      • Colannino NM
      • Azocar J
      • Seder RH
      • Hong SL
      • Deykin D
      Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.
      cytotoxic immunoglobulins,
      • Burns ER
      • Zucker-Franklin D
      Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells.
      primary vasculopathy,
      • Amorosi EL
      • Ultmann JE
      Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature.
      localized loss of fibrinolytic activity,
      • Kwaan HC
      The role of fibrinolysis in thrombotic thrombocytopenic purpura.
      prostacyclin deficiency,
      • Fitzgerald GA
      • Maas RL
      • Stein R
      • Oates JA
      • Roberts LJ
      Intravenous prostacyclin in thrombotic thrombocytopenic purpura.
      “exhausted” platelets,
      • Kitchens CS
      Studies of a patient with recurring thrombotic thrombocytopenic purpura.
      platelet-aggregating activity,
      • Lian EC-Y
      • Mui PTK
      • Siddiqui FA
      • Chiu AYY
      • Chiu LLS
      Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G.
      lack of immunoglobulin inhibitors of platelet-aggregating activity,
      • Aster RH
      Plasma therapy for thrombotic thrombocytopenic purpura: sometimes it works, but why? (editorial).
      presence of unusually large multimers of factor VIII:von Willebrand factor (VIII:vWF), and lack of immunoglobulin inhibitors of the large multimers of VIII:vWF.
      • Moake JL
      • Rudy CK
      • Troll JH
      • Weinstein MJ
      • Colannino NM
      • Azocar J
      • Seder RH
      • Hong SL
      • Deykin D
      Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.
      Although investigators agree that the intravascular hyaline thrombi are composed primarily of platelet aggregates, the sequence of events leading to this platelet agglutination remains controversial. Whether endothelial vascular damage initiates or results from the platelet agglutination is unclear. In support of a primary vasculopathy, subintimal “prethrombotic” hyaline deposits containing immunoglobulin have been observed in areas devoid of intraluminal thrombi. An immunoglobulin cytotoxic for cultured endothelial cells was isolated from the serum of three patients with TTP.
      • Burns ER
      • Zucker-Franklin D
      Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells.
      An alternative suggestion is that the vascular endothelial cell proliferation noted in TTP is simply reendo thelialization caused by previous local platelet agglutination.
      • Amorosi EL
      • Ultmann JE
      Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature.
      Endothelial damage may be responsible for the localized absence of fibrinolysis that distinguishes TTP from other disseminated intravascular coagulopathies; however, because platelets contain large quantities of inhibitors of both plasminogen activator and plasmin, the platelet-rich thrombi that characterize TTP are resistant to fibrinolysis.
      • Kwaan HC
      The role of fibrinolysis in thrombotic thrombocytopenic purpura.
      Other speculations about the cause of TTP include prostacyclin deficiency and “exhausted” platelets. Prostacyclin is a naturally occurring inhibitor of platelet aggregation and is synthesized by the vascular endothelium. A deficiency of this mediator has been demonstrated by several investigators, and infusion of prostacyclin has reversed platelet aggregation in vivo.
      • Fitzgerald GA
      • Maas RL
      • Stein R
      • Oates JA
      • Roberts LJ
      Intravenous prostacyclin in thrombotic thrombocytopenic purpura.
      Kitchens
      • Kitchens CS
      Studies of a patient with recurring thrombotic thrombocytopenic purpura.
      described “exhausted” platelets in a young woman with TTP, who had prolongation of the bleeding time and bruising just before thrombocytopenic relapse.
      The most cogent explanations reflect increasing understanding of the interactions of the platelet-aggregating activity described by Lian and associates,
      • Lian EC-Y
      • Mui PTK
      • Siddiqui FA
      • Chiu AYY
      • Chiu LLS
      Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G.
      • Lian EC-Y
      • Harkness DR
      • Byrnes JJ
      • Wallach H
      • Nunez R
      Presence of a platelet aggregating factor in the plasma of patients with thrombocytopenic purpura (TTP) and its inhibition by normal plasma.
      unusually large multimers of VIII:vWF, and the lack of inhibitors of these substances.
      • Kelton JG
      • Moore J
      • Santos A
      • Sheridan D
      Detection of a platelet-agglutinating factor in thrombotic thrombocytopenic purpura.
      • Marcus AJ
      Moschcowitz revisited (editorial).
      In 1977, Bukowski and colleagues
      • Bukowski RM
      • King JW
      • Hewlett JS
      Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura.
      demonstrated that most patients with TTP respond to plasma exchange. This finding suggested that the disease could be controlled by removal of a “toxic” substance that caused platelets to aggregate. Previous and subsequent successful treatment with plasma infusion alone led Lian and co-workers
      • Lian EC-Y
      • Harkness DR
      • Byrnes JJ
      • Wallach H
      • Nunez R
      Presence of a platelet aggregating factor in the plasma of patients with thrombocytopenic purpura (TTP) and its inhibition by normal plasma.
      and Aster
      • Aster RH
      Plasma therapy for thrombotic thrombocytopenic purpura: sometimes it works, but why? (editorial).
      to suggest that TTP resulted from a deficiency of a normal plasma component. Purification of the protein (or proteins) of the platelet-aggregating activity is currently in progress.
      • Siddiqui FA
      • Lian EC-Y
      Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma.
      Murphy and associates
      • Murphy WG
      • Moore JC
      • Kelton JG
      Calcium-dependent cysteine protease causes platelet aggregation of thrombotic thrombocytopenic purpura (TTP) (abstract).
      recently suggested that a calcium-dependent cysteine protease is responsible for the platelet-aggregating activity in TTP.
      Plasma from patients with TTP will induce agglutination of both washed platelets from normal donors and platelets from patients with TTP in remission. The platelet-aggregating activity of plasma from patients with TTP diminishes as a function of time during incubation with normal plasma at 37°C.
      • Lian EC-Y
      • Harkness DR
      • Byrnes JJ
      • Wallach H
      • Nunez R
      Presence of a platelet aggregating factor in the plasma of patients with thrombocytopenic purpura (TTP) and its inhibition by normal plasma.
      Platelet-aggregating activity is heterogeneous. Lian and colleagues
      • Lian EC-Y
      • Mui PTK
      • Siddiqui FA
      • Chiu AYY
      • Chiu LLS
      Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G.
      demonstrated that the plasma from a 3-year-old boy obtained during his second episode of TTP inhibited the platelet agglutination induced by plasma obtained during his first episode of TTP. An inhibitor of this platelet-aggregating activity has been found in plasma from patients with TTP. It is an immunoglobulin, and the activity resides in the Fab fragment.
      • Lian EC-Y
      • Mui PTK
      • Siddiqui FA
      • Chiu AYY
      • Chiu LLS
      Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G.
      Infusion of immunoglobulin has been shown to halt platelet agglutination both in vitro and in vivo. In acute TTP, perhaps an initial insult (such as pregnancy, drugs, infection, or tissue necrosis) triggers production of a platelet-agglutinating factor that causes, or is associated with, a subtle defect or deficiency in the humoral immune response during the disease state only.
      • Lian EC-Y
      • Mui PTK
      • Siddiqui FA
      • Chiu AYY
      • Chiu LLS
      Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G.
      Lian and Savaraj
      • Lian EC-Y
      • Savaraj N
      Effects of platelet inhibitors on the platelet aggregation induced by plasma from patients with thrombotic thrombocytopenic purpura.
      demonstrated that platelet agglutination induced in vitro did not necessitate the production of thromboxane A2, promote release of platelet granule contents, or alter metabolism of platelets or flux of calcium or magnesium ions.
      vWF is synthesized by megakaryocytes and vascular endothelium. It is present in platelet α granules and is stored in the Weibel-Palade bodies. In plasma, it circulates as multimers of 4 to 60 subunits (molecular weights 1 to 21 × 106) in a flexible filament that interacts with fibrinogen and is necessary for platelet adhesion to injured subendothelium at the high shear rates of rapid blood flow.
      • George JN
      • Nurden AT
      • Phillips DR
      Molecular defects in interactions of platelets with the vessel wall.
      In vitro, ristocetin (a positively charged substance) induces attachment of the largest VIII:vWF multimeric forms present in normal plasma to platelets and promotes platelet agglutination.
      • Moake JL
      • Rudy CK
      • Troll JH
      • Weinstein MJ
      • Colannino NM
      • Azocar J
      • Seder RH
      • Hong SL
      • Deykin D
      Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.
      In 1982, Moake and co-workers
      • Moake JL
      • Rudy CK
      • Troll JH
      • Weinstein MJ
      • Colannino NM
      • Azocar J
      • Seder RH
      • Hong SL
      • Deykin D
      Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.
      observed that the platelet agglutination in patients with TTP was similar to the platelet agglutination induced in vitro by large multimeric vWF components of VIII:vWF. They found unusually large VIII:vWF multimers in four patients with chronic relapsing TTP. The plasma levels of the multimers decreased during clinical relapses, a result that suggests binding to (and subsequent agglutination of) platelets. During clinical remissions, these same patients had abnormally high concentrations of these unusually large VIII:vWF multimers.
      Moake and associates
      • Moake JL
      • Rudy CK
      • Troll JH
      • Weinstein MJ
      • Colannino NM
      • Azocar J
      • Seder RH
      • Hong SL
      • Deykin D
      Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.
      suggested that patients with chronic TTP lack the ability to cleave large VIII:vWF multimers. They speculated that certain initiating factors (for example, pregnancy, drugs, infection, or tissue necrosis) release cationic polyamines (an in vivo ristocetin), which then neutralize the negatively charged platelet membrane and thus allow large multimers of VIII:vWF to be adsorbed and promote platelet agglutination. This sequence of events may result from a deficiency of or a defect in VIII:vWF depolymerase, which normally degrades these large multimers. The platelet agglutination induced by large multimers is inhibited by immunoglobulin (the activity is in the Fc fragment, in contrast to the Fab location of anti-platelet-agglutinating factor activity) by its binding to the platelet membrane Fc receptor.
      • Lian EC-Y
      • Mui PTK
      • Siddiqui FA
      • Chiu AYY
      • Chiu LLS
      Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G.
      Transfusion of a normal spectrum of factor VIII:vWF has reversed the hematologic abnormalities in one patient with TTP in whom unusually large vWF multimers had previously been demonstrated.
      • Miura M
      • Koizumi S
      • Nakamura K
      • Ohnu T
      • Tachinami T
      • Yamagami M
      • Taniguchi N
      • Kinoshita S
      • Abildgaard CF
      Efficacy of several plasma components in a young boy with chronic thrombocytopenia and hemolytic anemia who responds repeatedly to normal plasma infusions.
      In 1984, Kelton and colleagues
      • Kelton JG
      • Moore J
      • Santos A
      • Sheridan D
      Detection of a platelet-agglutinating factor in thrombotic thrombocytopenic purpura.
      suggested that both the platelet-aggregating activity described by Lian and co-workers
      • Lian EC-Y
      • Harkness DR
      • Byrnes JJ
      • Wallach H
      • Nunez R
      Presence of a platelet aggregating factor in the plasma of patients with thrombocytopenic purpura (TTP) and its inhibition by normal plasma.
      and the unusually large multimers of VIII:vWF described by Moake and associates
      • Moake JL
      • Rudy CK
      • Troll JH
      • Weinstein MJ
      • Colannino NM
      • Azocar J
      • Seder RH
      • Hong SL
      • Deykin D
      Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.
      were involved in the platelet agglutination that characterizes TTP. They described a method for the qualitative detection of platelet-agglutinating activity and noted that this activity was augmented by the addition of large VIII:vWF multimers.
      The concentration of platelet-associated immunoglobulin is frequently increased in patients with TTP.
      • Lian EC-Y
      • Mui PTK
      • Siddiqui FA
      • Chiu AYY
      • Chiu LLS
      Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G.
      • Morrion J
      • McMillan R
      Elevated platelet-associated IgG in thrombotic thrombocytopenic purpura.
      The level of platelet-associated antibody has been correlated with disease activity.
      • Kosty MP
      • Robinson WL
      • Seaward D
      • Shimozono B
      • Tani P
      • McMillan R
      Platelet-associated antibodies (PAIgG) in thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS): a significant correlation with disease activity (abstract).
      Perhaps immunoglobulins directed against platelet-agglutinating factor and large multimers of VIII:vWF are responsible for this increase.
      Figure 1 depicts the current theory of the potential pathogenesis of TTP. TTP is a syndrome with diverse causes and probably different pathogenetic mechanisms. An excellent review of the diverse pathogenesis of TTP has recently been published by Lian.
      • Lian EC-Y
      Pathogenesis of thrombotic thrombocytopenic purpura.
      In addition, extensive material on thrombotic microangiopathy organized by Kwaan
      should be of interest to hematologists.
      Figure thumbnail gr1
      Fig. 1Diagram of one hypothesis for pathogenesis of platelet agglutination in thrombotic thrombocytopenic purpura. (1) A noxious stimulus produces (A) transient platelet-agglutinating factor (PAF) and may promote (B) release of unusually large multimers of factor VIII:von Willebrand factor (VIII:vWF). (2) Because of a relative insufficiency, immunoglobulin (λ) is unable to neutralize PAF or the unusually large multimers of VIII:vWF. (3) PAF then neutralizes negatively charged platelet surfaces and thus promotes platelet agglutination. (4) Platelet agglutination is augmented by the presence of unusually large multimers of VIII:vWF.

      TREATMENT

      The therapeutic effect of single agents in patients with TTP is difficult to determine because multiple treatment modalities are generally used concomitantly for this life-threatening disease. Treatment options include the following: corticosteroids, antiplatelet agents (such as dextran, sulfinpyrazone, aspirin, or dipyridamole), prostacyclin, infusion of plasma, plasma exchange, Vinca alkaloids, splenectomy, and infusion of immunoglobulin. Currently, initial therapy generally includes antiplatelet agents (aspirin and dipyridamole), corticosteroids, and either plasma exchange or infusion of fresh-frozen plasma.
      Although in vitro data suggest that platelet inhibitors fail to prevent platelet aggregation,
      • Lian EC-Y
      • Savaraj N
      Effects of platelet inhibitors on the platelet aggregation induced by plasma from patients with thrombotic thrombocytopenic purpura.
      the survival rate of patients treated with antiplatelet agents (aspirin and dipyridamole) and concurrent plasma manipulation is improved.
      • Kennedy SS
      • Zacharski LR
      • Beck JR
      Thrombotic thrombocytopenic purpura: analysis of 48 unselected cases.
      Perhaps the inhibition of platelet adhesion and of further platelet aggregation and release in vivo explains the beneficial effects of platelet inhibitors in patients with TTP.
      • Lian EC-Y
      • Savaraj N
      Effects of platelet inhibitors on the platelet aggregation induced by plasma from patients with thrombotic thrombocytopenic purpura.
      The ineffectiveness of platelet inhibitors (and the bleeding complications) noted by one group of investigators
      • Rosove MH
      • Ho WG
      • Goldfinger D
      Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura.
      may have been due to suppression of the platelet-inhibiting effect of prostacyclin.
      • Wood LA
      Letter to the editor.
      Infusion of prostacyclin has reversed TTP in vivo but is associated with severe hypotension from its vasodilatory effects.
      • Fitzgerald GA
      • Maas RL
      • Stein R
      • Oates JA
      • Roberts LJ
      Intravenous prostacyclin in thrombotic thrombocytopenic purpura.
      One brief controlled trial demonstrated an increase in fatal cerebral hemorrhage with use of heparin.
      • Kennedy SS
      • Zacharski LR
      • Beck JR
      Thrombotic thrombocytopenic purpura: analysis of 48 unselected cases.
      Although platelet transfusions occasionally have been given because of bleeding associated with severe thrombocytopenia, Harkness and co-workers
      • Harkness DR
      • Byrnes JJ
      • Lian EC-Y
      • Williams WD
      • Hensley GT
      Hazard of platelet transfusion in thrombotic thrombocytopenic purpura.
      described a young female patient with TTP who had rapid deterioration of the central nervous system (with autopsy evidence of extensive deposition of platelet aggregates within the small blood vessels of the brain) immediately after the transfusion of platelets. This outcome raises the possibility that platelet transfusion may fuel ongoing platelet agglutination. Moreover, Gordon and associates
      • Gordon LI
      • Kwaan HC
      • Rossi EC
      Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy.
      extended this observation by noting that, in addition to platelet transfusion, reaccumulation of the circulating platelet pool (as a result of reversal of the disease process) also may be associated with clinical deterioration. They suggested that antiplatelet therapy be delayed until platelet counts begin to increase steadily in response to initial treatment (plasmapheresis with fresh-frozen plasma and corticosteroids).
      Infusion of fresh-frozen plasma has been the basis of successful treatment of TTP, perhaps by supplying the immunoglobulin inhibitors to platelet-agglutinating factor and VIII:vWF. Plasma exchange may be used if infusion of fresh-frozen plasma is inadequate or complicated by volume overload. The added efficacy of plasma exchange over infusion of fresh-frozen plasma
      • Ansell J
      • Beaser RS
      • Pechet L
      Thrombotic thrombocytopenic purpura fails to respond to fresh frozen plasma infusion.
      in some patients may reflect the removal of large VIII:vWF multimers or platelet-aggregating activity.
      Other treatment options include splenectomy, Vinca alkaloids, and infusion of immunoglobulin. The demonstrated effectiveness of infusion of immunoglobulin in halting platelet agglutination in patients with TTP
      • Lian EC-Y
      • Mui PTK
      • Siddiqui FA
      • Chiu AYY
      • Chiu LLS
      Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G.
      • Aster RH
      Plasma therapy for thrombotic thrombocytopenic purpura: sometimes it works, but why? (editorial).
      makes such treatment an attractive option. In one recently reported case, TTP was treated successfully with infusion of high doses of immunoglobulin after the failure of plasmapheresis, exchange transfusion, splenectomy, antiplatelet agents, glucocorticoids, and vincristine.
      • Finn NG
      • Wang JC
      • Hong KJ
      High-dose intravenous γ-immunoglobulin infusion in the treatment of thrombotic thrombocytopenic purpura.

      CONCLUSION

      TTP has changed from a disease once universally fatal to an illness that, when recognized, has a remission rate exceeding 90%. Increasing success in the treatment of TTP with the use of plasma and its components is unlocking etiologic secrets.

      ACKNOWLEDGMENT

      I thank Robert M. Petitt, M.D. (Division of Hematology and Internal Medicine), for his thoughtful suggestions and Denise R. King for preparation of the submitted manuscript.

      REFERENCES

        • Moschcowitz E
        Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.
        Proc NY Pathol Soc. 1924; 24: 21-24
        • Moschcowitz E
        An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease.
        Arch Intern Med. 1925; 36: 89-93
        • Petitt RM
        Thrombotic thrombocytopenic purpura: a thirty year review.
        Semin Thromb Hemost. 1980; 6: 350-355
        • Ridolfi RL
        • Bell WR
        Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature.
        Medicine. 1981; 60: 413-428
        • Amorosi EL
        • Ultmann JE
        Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature.
        Medicine. 1966; 45: 139-159
        • Weinstein L
        Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension and pregnancy.
        Am J Obstet Gynecol. 1982; 142: 159-167
        • Kwaan HC
        The role of fibrinolysis in thrombotic thrombocytopenic purpura.
        Semin Hematol. 1987; 24: 101-109
        • Moake JL
        • Rudy CK
        • Troll JH
        • Weinstein MJ
        • Colannino NM
        • Azocar J
        • Seder RH
        • Hong SL
        • Deykin D
        Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.
        N Engl J Med. 1982; 307: 1432-1435
        • Burns ER
        • Zucker-Franklin D
        Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells.
        Blood. 1982; 60: 1030-1037
        • Fitzgerald GA
        • Maas RL
        • Stein R
        • Oates JA
        • Roberts LJ
        Intravenous prostacyclin in thrombotic thrombocytopenic purpura.
        Ann Intern Med. 1981; 95: 319-322
        • Kitchens CS
        Studies of a patient with recurring thrombotic thrombocytopenic purpura.
        Am J Hematol. 1982; 13: 259-267
        • Lian EC-Y
        • Mui PTK
        • Siddiqui FA
        • Chiu AYY
        • Chiu LLS
        Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G.
        J Clin Invest. 1984; 73: 548-555
        • Aster RH
        Plasma therapy for thrombotic thrombocytopenic purpura: sometimes it works, but why? (editorial).
        N Engl J Med. 1985; 312: 985-987
        • Lian EC-Y
        • Harkness DR
        • Byrnes JJ
        • Wallach H
        • Nunez R
        Presence of a platelet aggregating factor in the plasma of patients with thrombocytopenic purpura (TTP) and its inhibition by normal plasma.
        Blood. 1979; 53: 333-338
        • Kelton JG
        • Moore J
        • Santos A
        • Sheridan D
        Detection of a platelet-agglutinating factor in thrombotic thrombocytopenic purpura.
        Ann Intern Med. 1984; 101: 589-593
        • Marcus AJ
        Moschcowitz revisited (editorial).
        N Engl J Med. 1982; 307: 1447-1448
        • Bukowski RM
        • King JW
        • Hewlett JS
        Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura.
        Blood. 1977; 50: 413-417
        • Siddiqui FA
        • Lian EC-Y
        Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma.
        J Clin Invest. 1985; 76: 1330-1337
        • Murphy WG
        • Moore JC
        • Kelton JG
        Calcium-dependent cysteine protease causes platelet aggregation of thrombotic thrombocytopenic purpura (TTP) (abstract).
        Blood. 1986; 68: 310a
        • Lian EC-Y
        • Savaraj N
        Effects of platelet inhibitors on the platelet aggregation induced by plasma from patients with thrombotic thrombocytopenic purpura.
        Blood. 1981; 58: 354-359
        • George JN
        • Nurden AT
        • Phillips DR
        Molecular defects in interactions of platelets with the vessel wall.
        N Engl J Med. 1984; 311: 1084-1098
        • Miura M
        • Koizumi S
        • Nakamura K
        • Ohnu T
        • Tachinami T
        • Yamagami M
        • Taniguchi N
        • Kinoshita S
        • Abildgaard CF
        Efficacy of several plasma components in a young boy with chronic thrombocytopenia and hemolytic anemia who responds repeatedly to normal plasma infusions.
        Am J Hematol. 1984; 17: 307-319
        • Morrion J
        • McMillan R
        Elevated platelet-associated IgG in thrombotic thrombocytopenic purpura.
        JAMA. 1977; 238: 1944-1945
        • Kosty MP
        • Robinson WL
        • Seaward D
        • Shimozono B
        • Tani P
        • McMillan R
        Platelet-associated antibodies (PAIgG) in thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS): a significant correlation with disease activity (abstract).
        Blood. 1986; 68: 111a
        • Lian EC-Y
        Pathogenesis of thrombotic thrombocytopenic purpura.
        Semin Hematol. 1987; 24: 82-100
      1. Semin Hematol. 1987; 24 (141–201): 69-139
        • Kennedy SS
        • Zacharski LR
        • Beck JR
        Thrombotic thrombocytopenic purpura: analysis of 48 unselected cases.
        Semin Thromb Hemost. 1980; 6: 341-349
        • Rosove MH
        • Ho WG
        • Goldfinger D
        Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura.
        Ann Intern Med. 1982; 96: 27-33
        • Wood LA
        Letter to the editor.
        Ann Intern Med. 1982; 96: 680-681
        • Harkness DR
        • Byrnes JJ
        • Lian EC-Y
        • Williams WD
        • Hensley GT
        Hazard of platelet transfusion in thrombotic thrombocytopenic purpura.
        JAMA. 1981; 246: 1931-1933
        • Gordon LI
        • Kwaan HC
        • Rossi EC
        Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy.
        Semin Hematol. 1987; 24: 194-201
        • Ansell J
        • Beaser RS
        • Pechet L
        Thrombotic thrombocytopenic purpura fails to respond to fresh frozen plasma infusion.
        Ann Intern Med. 1978; 89: 647-648
        • Finn NG
        • Wang JC
        • Hong KJ
        High-dose intravenous γ-immunoglobulin infusion in the treatment of thrombotic thrombocytopenic purpura.
        Arch Intern Med. 1987; 147: 2165-2167